Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2020
Number of items: 2.

2022

Tan, Daniel S. W., Kim, Sang-We, Aix, Santiago Ponce, Sequist, Lecia, V, Smit, Egbert F., Yang, James C. H., Hida, Toyoaki, Toyozawa, Ryo, Felip, Enriqueta, Wolf, Juergen, Grohe, Christian, Leighl, Natasha B., Riely, Gregory, Cui, Xiaoming, Zou, Mike, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2022). Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur. J. Cancer, 172. S. 276 - 287. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

2020

Tan, Daniel Shao-Weng, Leighl, Natasha B., Yang, James Chih-Hsin, Riely, Gregory J., Sequist, Lecia, V, Toyozawa, Ryo, Wolf, Juergen, Felip, Enriqueta, Kim, Sang-We, Aix, Santiago Ponce, Smit, Egbert F., Hida, Toyoaki, Grohe, Christian, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2020). Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Fri Apr 26 21:01:42 2024 CEST.